Method of achieving high specificity of gene editing
The all-RNA CRISPR/CAS system addresses the integration and control issues of traditional CRISPR/CAS methods by using mRNA-based delivery for precise and efficient genome editing in mammalian cells, reducing off-target effects and genomic integration.
Patent Information
- Application Number
- JP2024135748
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-07-13
- Filing Date
- 2024-08-15
- Publication Date
- 2024-11-26
AI Technical Summary
Existing CRISPR/CAS systems for genome editing in mammalian cells rely on DNA vectors or retroviruses/lentiviruses, which can integrate randomly into the host genome, leading to unpredictable expression levels and off-target effects, and are difficult to control.
An all-RNA delivery method using Cas enzyme and guide RNA, without viral elements, for precise genome editing with minimal off-target effects, utilizing mRNA-based systems for efficient delivery and controlled enzyme expression.
Achieves high specificity and efficiency in genome editing with reduced off-target changes, suitable for difficult-to-maintain cells like pluripotent stem cells, and minimizes genomic footprints.
Smart Images

Figure 2024164090000040 
Figure 2024164090000041 
Figure 2024164090000042
Abstract
Description
[Technical field]
[0001] Related Applications This application claims the benefit of priority to U.S. Provisional Patent Application No. 62 / 697,955, filed July 13, 2018, which is incorporated by reference herein, including any drawings. FIELD OF THEINVENTION The present disclosure relates to methods, compositions, and kits and systems that can be used in DNA modification, including DNA sequence knock-in or knock-out, DNA mutation, DNA epigenetic modification, chromatin modification in a DNA sequence-specific manner, and other types of genome editing.More specifically, the present disclosure relates to the system of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), and the method that can deliver its components, mutations, fusions, and variations without using any carrier vector.The present invention specifically teaches the process of genome editing with specificity and precision that allows single nucleotide replacement, including difficult host cells as well as pluripotent stem cells. [Background technology]
[0002] Background of the disclosure Previously reported CRISPR / CAS studies in cultured mammalian cells relied on DNA vectors or retroviruses / lentiviruses for delivery of both sgRNA and Cas enzymes. See, e.g., U.S. Patent No. 8,697,359. Plasmid DNA exhibits the potential for random DNA integration into the host genome, which is widely known in the art (e.g., Valamehr et al. 2014 Stem Cell (See Reports). Retroviral or lentiviral vectors for delivery of cas enzyme genes or gRNAs need to integrate into the host genome before they can deliver the payload they carry as RNA or protein molecules. In addition, it is difficult to control the level of expression from either plasmid or viral vectors. Although a general correlation exists between the expression level of genes encoded on these vectors and the copy number of the vector, the relationship is nonlinear and highly variable. [Prior art documents] [Patent documents]
[0003] [Patent Document 1] U.S. Pat. No. 8,697,359 Summary of the Invention [Means for solving the problem]
[0004] Summary of the Invention A novel method for highly efficient DNA sequence modification is disclosed. The method can be used to edit chromosomes to manipulate cell markers through gene insertion, or to create epigenetic changes by using cas9-enzyme fusions, where the enzyme can be a DNA epigenetic modification enzyme or a chromatin modification enzyme, etc. In addition to the dramatic increase in genome editing efficiency by the invented process, the novel technology also differs from all previously known technologies in that the CRISPR / CAS systems can function in a "clean" manner, i.e., they are not in contact with any virus or carried DNA molecules that can be inserted into chromosomes at unintended locations. It is also noted that the disclosed system can produce previously unattainable efficiencies while keeping off-target changes to a minimum. The utility of the present invention can be found in virtually all fields involving DNA editing or epigenetic modification. In contrast, the 8,697,359 patent does not teach how to provide a system in which CRISPR / Cas can be efficiently obtained in eukaryotic cells while minimizing the potential problem of unintended genome changes.
[0005] The present disclosure provides an RNA-based system that provides both Cas enzymes and guide RNAs, and in cases involving DNA break repair, "patch" template RNA or DNA, all without the need for any exogenous DNA molecules (unless a DNA template is the preferred template for DNA break repair). The all-RNA CRISPR / Cas (as used herein, the term "all-RNA" refers primarily to the delivery of components of the CRISPR / Cas machinery and does not exclude DNA as a template) system disclosed herein does not require any viral elements that may cause problems for human clinical use of the process or the resulting cells. This system can be provided as a method, process, or reagent kit to achieve CRISPR / Cas-facilitated gene disruption via indels, genome sequence editing to single base accuracy, or gene replacement via break repair and replacement after CRISPR / Cas treatment in cultured cells (including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs)) with enhanced efficiency and specificity compared to what has been shown in the art.
[0006] An important aspect of the present disclosure is the use of an all-RNA delivery method that allows for a polynucleotide-guided genome cleavage system in eukaryotic cells, with a design that is particularly useful in mammalian cells, and a process that has been empirically developed for difficult-to-maintain cells that easily escape from a pluripotent state when perturbed (e.g., pluripotent stem cells). The disclosed method also works in tissue stem cells (e.g., including but not limited to neural progenitor cells, oligodendrocyte progenitor cells, mesenchymal stem cells, hematopoietic stem cells, etc.). Provided herein is a method for introducing gRNA as in vitro transcribed (IVT) RNA and Cas enzyme as mRNA using common nucleoside triphosphates (NTPs) or NTPs with chemical modifications.
[0007] Another aspect of the present disclosure is that in addition to being footprint-free (unlike plasmid vectors that can be integrated into genomes), using RNA as a delivery format allows for higher enzyme activity levels of Cas, which results in higher success rates.In another disclosure, high levels of enzyme activity can be concentrated in a short time frame in a more highly controllable manner.The transient nature of RNA-mediated high enzyme expression levels provides an ideal composition for the purpose of chromosome modification.Short bursts of enzyme expression provide an additional benefit in reducing off-target effects, because the long-term presence of enzymes (e.g., from plasmid DNA vectors or integrated viral vectors) can result in continuous off-target effects.
[0008] In another aspect of the present disclosure, gRNA is delivered to Cas mRNA in various ratios, sometimes involving multiple delivery via transfection. Once cas mRNA is translated into Cas protein, the protein appears to have a longer half-life than mRNA and gRNA. The present disclosure shows that by adjusting the amount of gRNA (which can be referred to as gRNA / cas mRNA ratio), the above process can produce precise single-base editing in addition to the more commonly observed longer insertions or deletions or rearrangements of chromosomes. Example 4 of the present disclosure shows the increased accuracy of the disclosed method by showing the successful example of how to change a single base on a chromosome using an all-RNA methodology in human iPSC clones.
[0009] A stumbling block to using mRNA to achieve long-term protein expression in cell culture is that RNA itself can be highly immunogenic (Kawai and Akira, 2007; Randall and Goodbourn, 2008). Mammalian cells are equipped with a group of sensors that can detect exogenous RNA and activate antiviral defense pathways that stimulate cytostatic and apoptotic pathways and alert neighboring cells to the very same stimuli via secreted signals such as interferon α and β. The more widely expressed sensors (e.g., TLR3 and RIG-I) primarily detect double-stranded RNA (the production of dsRNA is a unique feature of the life cycle of many viruses) but can also be activated by synthetic mRNA (Kormann et al., 2011). In the course of iPSC generation using mRNA, techniques have been found to minimize the immunogenic response to synthetic mRNA (Warren et al., 2010). The most practical approach involves the incorporation of modified nucleobases and supplementing the culture medium with a recombinant version of the B18R protein, when human cells are treated with modified mRNA, an extracellular decoy receptor for type I interferon naturally expressed by vaccinia virus to blunt the immune response to infection.
[0010] In one embodiment, the delivery of the all-RNA CRISPR / Cas system to human cells was accompanied by the addition of B18R. In another embodiment, the RNA molecule can be delivered to human or non-human cells if the RNA molecule is sufficiently purified to remove aberrant transcripts during in vitro transcription. In another embodiment, the delivered RNA molecule is modified to avoid immune detection of cells. In summary, the novel CRISPR / Cas system offers technical feasibility for genome engineering in these aspects: polynucleotide guided, no need for protein engineering for each target site; well-controlled process via RNA delivery that leaves no genome footprint; easy to achieve desired modification efficiency in different cell types by varying the treatment time; higher success rate and lower off-target effects than ZFN or TALEN or previously reported CRISPR / CAS methodologies due to the designed higher enzymatic activity in a short time frame; precise genome modification in a more efficient process that can be performed in pluripotent stem cells without perturbing the stem cell state and is made possible, at least in part, by a previously unknown, nearly uncontrollable factor-gRNA / cas-mRNA ratio (which is not optimal given that plasmids, viral vectors, and ribonucleoproteins (RNPs) are used). Compared to recently published CRISPR / CAS systems, the disclosed all-RNA format uniquely allows for the minimization of unwanted chromosomal changes.
[0011] The method disclosed herein is based on the unexpected advantage of regulating the dosage of gRNA and CAS enzyme via cas mRNA.We disclose the time and frequency of delivery, and the method for delivery into human cells, and by simple extension, any mammalian cell; using a similar scheme, the CRISPR / CAS system described herein can also be used in other types of cells (e.g., plant, yeast, bacterial).
[0012] In an embodiment of the disclosed aspect discussed above, a method for genome editing is disclosed herein, using a combination of synthetic mRNA and sgRNA encoding Cas9 enzyme.In an embodiment of this aspect, the mRNA and sgRNA encoding Cas9 comprises a 5' diguanosine cap and a poly(A) tail, and modified nucleotides that make the mRNA less toxic to cells.In some embodiments, the modified nucleotides comprise 5-methyl-cytosine, 2-thio-uracil, or pseudouracil.In some embodiments, the mRNA encoding Cas9 is provided together with B18R.
[0013] In another aspect of the present disclosure, disclosed herein is a method for making precise changes in DNA or genomes using mutant forms of Cas9 protein that contain mutations in one or both of the endonuclease genes of Cas9 protein.In an embodiment of this aspect, Applicant has generated three non-naturally occurring mutant Cas9 proteins that have mutations in the endonuclease active site of Cas9 protein.These mutant Cas9 proteins are encoded by SEQ ID NOs: 2, 3 and 4.
[0014] Another aspect of the present disclosure is a method that allows for highly accurate repair of point mutations based on the use of the mutated Cas9 protein.In one embodiment, the non-naturally occurring CRISPER-Cas system comprises an mRNA that codes for a mutated Cas9 protein with a mutation in its nuclease active site, and at least one mRNA that codes for a guide RNA that generates the mutated Cas9 protein and guide RNA when it enters a cell.After entering, the Cas9 protein and guide RNA target and hybridize to a target sequence of DNA with a single point mutation, which corrects the mutation in the target sequence when the mutated Cas9 protein and guide RNA act.
[0015] In one embodiment, disclosed herein is a method for genome editing using a combination of synthetic mRNA and sgRNA encoding a Cas9 enzyme. In some embodiments, the Cas9 encoding mRNA and sgRNA include a 5' diguanosine cap and a poly(A) tail. In some embodiments, a template that facilitates DNA cleavage is also provided. The template can be a double-stranded or single-stranded DNA molecule. In some embodiments, the template is an RNA molecule. In one embodiment of this method, the Cas9 has a mutation that destroys one of the two endonuclease active sites. The Cas9 protein mutant is encoded by SEQ ID NO:2 or SEQ ID NO:3. One Cas9 protein mutant has a mutation in both endonuclease active sites and is encoded by SEQ ID NO:4. In another embodiment of this method, Cas9 is fused to another enzyme that can alter epigenetic markers on either DNA or chromatin proteins. In some embodiments of this method, the molar ratio of Cas9 mRNA:sgRNA is between 1:1,000 and 1,000:1. In some embodiments of the above methods, the molar ratio of Cas9 mRNA:sgRNA is between 1:1,000 and 1,000:1. In some embodiments, the molar ratio of Case9 mRNA:sgRNA is 1:1,000; 1:950; 1:900; 1:850; 1:800; 1:750; 1:700; 1:650; 1:600; 1:550; 1:500, 1:450; 1:400; 1:350; 1:300; 1:250; 1:200; 1:150; 1:100; 1:50; 1:40; 1:30; 1:25; 1:20; 1:15; 1:10; 1:9; 1:8; 1:7; 1:6; 1:5; 1:4.75; 1:4.5; 1:4.25; 1:4; 1:3.75; 1:3.5; 1.3.25; 1:3; 1:2.9; 1:2.8; 1:2.75; 1:2.7; 1:2.6; 1:2.5; 1:2.4; 1:2.3; 1:2.25; 1:2.2; 1:2.1; 1:2; 1:1.9; 1:1.8; 1:1.7; 1:1.6; 1:1.5; 1:1.4; 1:1.3; 1:1.2; 1:1.1; 1:1; 1.1:1; 1.2:1; 1.3:1; 1.4:1; 1.5:1; 1.6:1; 1.7:1; 1.8:1; 1.9:1; 2:1; 2.1:1; 2.2:1; 2.25:1; 2.3:1; 2.4:1; 2.5:1; 2.6:1; 2.7:1; 2.75:1; 2.8:1; 2.9:1; 3.0:1; 3.25:1; 3.5:1; 3.75:1; 4:1; 4.25:1; 4.5:1; 4.75:1; 5:1; 6:1; 7:1; 8:1; 9:1; 10:1; 15:1; 20:1; 25:1; 30:1; 40:1; 50:1; 100:1; 150:1; 200:1; 250:1; 300:1; 350:1; 400:1; 450:1; 500:1; 550:1; 600:1; 650:1; 700:1; 750:1; 800:1; 850:1; 900:1; 950:1; 1,0000:1, or any range of ratios between any two of the described ratios.In another embodiment, multiple sgRNAs that target different sites in combination with mRNA molecules that code for one or more different Cas9 enzymes from different species and with different mutations are introduced into the same cell.In the methods disclosed herein, the repair template is positioned at the DNA cleavage site through fusion to sgRNA as one molecule.In some embodiments, the repair template is positioned at the DNA cleavage site through fusion to an aptamer that binds to Cas9.
[0016] The precision - operable nature of the disclosed methods allows the disclosed technology to be used to treat human diseases (e.g., methylmalonyl-CoA mutase deficiency, 3-methylcrotonyl-CoA carboxylase deficiency, Gaucher disease, Ogden syndrome, Lesch-Nyhan syndrome, Leigh disease, pyruvate dehydrogenase deficiency, 3-hydroxy-3-methylglutaryl-CoA lyase deficiency, carboxylase deficiency, late-onset multiple fumarase deficiency, ... The present invention is most suitable for generating cells to treat a variety of conditions, including, but not limited to, chronic myelopathy, fibrodysplasia ossificans progressiva, n-glycanase 1 deficiency, X-linked mental retardation of the siderius type, phenylketonuria, Tay-Sachs disease, α-galactosidase A deficiency, sickle cell anemia, and maple syrup urine disease.
[0017] The invention will now be described with reference to the drawings. [Brief description of the drawings]
[0018] [Figure 1] Figure 1. IVT template preparation for generating cas9 mRNA sgRNA. 2% agarose gel shows bands of purified linear DNA generated by cutting plasmids encoding cas9 or sgRNA genes with restriction enzymes.
[0019] [Diagram 2] Figure 2. mRNA encoding the Cas9 enzyme and sgRNA against the fluorescent protein mWasabi. A 2% agarose gel shows bands for cas9 mRNA with a poly(A) tail and sgRNA against mWasabi.
[0020] [Diagram 3]Figure 3. The effect of disrupting expression of the mWasabi gene integrated into the chromosome of human 293 cells. A constant amount of cas9 mRNA and increasing amounts of sgRNA were delivered to 293-mWasabi cells in a single transfection. Control wells did not receive any RNA but were treated with the same transfection reagent.
[0021] [Figure 4] Figure 4. An example of using the all-RNA CRISPR / CAS system to generate mutations in human genes. Each dsDNA breakpoint can be directed by a pair of sgRNAs. Sequence replacement can be performed at either one or two breakpoints as shown in the figure. When four sgRNAs are relied upon to direct the replacement, the specificity is maximized.
[0022] [Diagram 5] Figure 5. Example of the use of an all-RNA CRISPR / CAS system to generate mutations in human genes with a dimerized Cas9 enzyme encoded by modified mRNA. The CRISPR / CAS-mediated genome editing specificity described above can be further enhanced with dimerized Cas9, especially when delivered via the mRNA code. Other domains can be fused to Cas9 in a similar manner for epigenetic modification.
[0023] [Figure 6] Figure 6. Primer design for qPCR. This design enabled detection of single base changes in iPSCs by real-time PCR.
[0024] [Figure 7] Figure 7. Example of an amplification Ct curve. The curve shows how the mutation rate at a given location on a chromosome is detected by a well-designed qPCR.
[0025] [Figure 8]Figure 8. Sample amplification plots for clonal amplicon library screening. Although qPCR screening of clonal amplicon libraries generally produces high variation, there are a few low Ct outlier wells considering the bulk population with HDR efficiency of about 1%. Once left-shifted Ct outliers are identified, the corresponding wells are expanded in duplicate plates.
[0026] [Figure 9] Figure 9. Sample chromatograms for clonal amplicon library screening. A single base switch from T to G was achieved in one iPSC clone heterozygous for the intended MEF2C locus. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0027] Detailed Description of the Invention When describing the present invention, all terms not defined herein have their general meaning recognized in the art. To the extent that the following description is directed to a specific embodiment or specific use of the present invention, it is illustrative only and does not limit the claimed invention. The following description is intended to cover all changes, modifications and equivalents that fall within the spirit and scope of the present invention.
[0028] Others in the field have attempted to use in vitro transcribed cas mRNA and gRNA with either no success or limited results. For example, Kouranova et al. (Hum Gene Ther. 2016 Jun 1; 27(6): 464-475.) tried plasmids, RNA, and protein as delivery formats for Cas in comparison with ZFNs. They concluded that "Unlike our experience with ZFN mRNA, co-transfection of in vitro transcribed Cas9 mRNA or Cas9-expressing plasmid DNA with in vitro transcribed sgRNA rarely resulted in efficient cleavage at the target site in the rat C6 cell line by nucleofection." Liang et al. (Journal of Biotechnology, Volume 208, 20 August 2015, 44-53) also compared plasmids, mRNA, and protein for delivery of CRISPR / CAS to various mammals. They showed that both mRNA and RNP-forming CAS proteins functioned to create indels, a mechanism for precisely editing bases on chromosomes through homology-directed recombination (HDR), whereas the much more difficult problem and often more desirable outcome via CRISPR / CAS was not addressed or presented, and was highly unlikely to be achieved in their system. Others have used RNA molecules for CRISPR / CAS, but only in fertilized animal eggs or embryos via microinjection, with mixed results (Wu et al. Cell Stem cell, Volume 13, Issue 6, 5 December 2013, 659-662; Liang et al. Protein & Cell, May 2015, Volume 6, Issue 5, pp 363-372; Hruscha et al. Development 2013 140: 4982-4987). None of these reports were based on the transfection process as disclosed herein being successfully used with mammalian cell cultures maintained in containers, including particularly difficult-to-maintain cells such as pluripotent stem cells.
[0029] In one aspect of the present disclosure, mRNA-based encoding wild-type cas9 is derived from different bacterial species (e.g., Streptococcus pyogenes, Streptococcus mutans, Campylobacter jejuni, N. meningitidis, Escherichia coli, Francisella novicida, and other species known to contain type II CRIPSR systems (Fonfara et al., 2013)). Such Cas9 enzyme genes or other Cas enzymes can be cloned from either bacterial genomic DNA or cDNA using cloning techniques known in the art.
[0030] In another aspect, the cas9 gene is cloned behind a promoter (e.g., the promoter of bacterial phage T7 RNA polymerase, T3 RNA polymerase, or Sp6 RNA polymerase, or other RNA polymerase). A cassette containing the promoter, DNA encoding cas9, and a fragment encoding a poly(A) tail for mRNA suitable for stability and expression in eukaryotic cells can be used as a linear template for in vitro translation (IVT) or cloned into a vector such as a plasmid, phagemid, or other carrier of DNA sequences (e.g., FIG. 1). One example of such a vector is the pIVT plasmid we previously described (Warren et al., 2012).
[0031] Disclosed herein is a method for generating mRNA encoding a Cas protein. In one embodiment, the mRNA is generated by in vitro transcription under optimized conditions as described herein. One embodiment of the disclosure is a synthetic mRNA transcript that serves as an efficient template for translation in living cells by incorporating a 5' diguanosine cap and a poly(A) tail. The cap and tail can be enzymatically or co-transcriptionally incorporated into the IVT transcript. Benefits of enzymatic capping include high RNA yield, low cost, and the possibility of generating nearly pure capped RNA. However, since there is no easy way to check that enzymatic capping is proceeding successfully, it is preferable to use a more robust co-transcriptional capping approach. In this scheme, a synthetic cap analog is included at a high concentration in the IVT reaction buffer (the cap is preferentially incorporated instead of GTP at the 5' end of the transcript based on the respective reaction concentrations of the reagents). Another embodiment is to use a co-transcriptional approach into a polyadenylate transcript:poly(dA:dT) tract at the end of the IVT template that drives the incorporation of the tail by RNA polymerase. It is also an embodiment of the present disclosure that the poly(A) tail of the cas9 mRNA is added to the end of the coding region by a polyadenylation polymerase (Figure 2).
[0032] In one aspect, in vitro transcription is preferably carried out with modified nucleotide triphosphate (NTP) (e.g., 5-methyl-cytosine, 2-thio-uracil, or pseudouracil), or other modified nucleotides that can replace unmodified nucleotides in RNA molecules without significantly changing the function of RNA.The use of modified nucleotides helps to reduce cellular immune response, which is particularly important when repeated delivery of mRNA to host cells is required to achieve a desired level of genome modification in the host cells, or when the host cells are hypersensitive to exogenous RNA molecules.
[0033] The present disclosure further relates to the generation of sgRNA. Previously, sgRNA guided by CRISPR / CAS has been introduced via DNA or viral vectors. Thereby, the sgRNA-encoding DNA is placed behind a promoter (e.g., U6 or H1 promoter) that can drive the transcription of short RNA. In one embodiment of the present disclosure, the sgRNA-encoding DNA is placed behind a promoter suitable for in vitro transcription (e.g., T7, T3, or Sp6 promoter) (Figure 1). The cassette containing the promoter and the sgRNA-encoding DNA can be used as a linear template or can be cloned into a vector (e.g., a plasmid, a phagemid, or other carrier of DNA sequence). Transcription termination can also be achieved by having a transcription terminator sequence. One example of such a vector is the pIVT plasmid previously described (Warren et al., 2012). In one embodiment of the present disclosure, the sgRNA is generated by IVT using modified or unmodified NTPs (Figure 2).
[0034] One aspect of the present disclosure relates to the design of Cas9 enzyme. Wild-type Cas9 enzyme naturally has two endonuclease functional domains, SEQ ID NO:1. By selective point mutation as described herein, the Cas9 enzyme can be converted from a dsDNA cleavage enzyme to a single-stranded DNA (ssDNA) nicking enzyme (e.g., SEQ ID NO:2, SEQ ID NO:3). Furthermore, when two such nicking enzymes are on opposite strands of a dsDNA molecule, double-strand breaks can still be made, but in contrast to the double-strand breaks made by wild-type Cas9, two sgRNAs are required, thereby providing additional sequence specificity to the process (Figure 4). In one example, mRNA is made to express such a mutant of Cas9 that nicks one strand when guided by one sgRNA. In another embodiment, the cas9 mRNA is further mutated to remove both of its endonuclease domains (SEQ ID NO: 4) and encodes a version of Cas9 fused to an artificial nuclease domain, such as that of the restriction enzyme FokI or other such restriction enzymes (Figure 5). The resulting mutated form of Cas9 must form a dimer to function as an endonuclease, and requires the target sites defined by a pair of sgRNA sequences to be in close proximity together, preferably between about 5-30 nucleotides or between about 10-20 nucleotides (nts), or between about 12-18 nts apart, to provide further specificity.
[0035] Another aspect of the present invention is related to the selection of CRISPR / CAS target site. The design of preferred sgRNA matching site on eukaryotic genome has been well established. In one embodiment of the present invention, in order to maximize target specificity during chromosome knock-in process (replacing a segment of chromosome sequence (which can be as short as 1 nt) with another segment by providing DNA template), it is disclosed herein that double-strand break is created by using either nicking Cas9 mutant or Cas9-FokI fusion when selecting target site. An example is illustrated in Figure 4.
[0036] In a further embodiment, the Cas9 or its nicked or blunt mutants are fused in frame to epigenetic modification enzymes (e.g., protein arginine methyltransferases PRMT1 and PRMT4 (CARM1), DNA methyltransferases, histone methyltransferases, histone acetyltransferases, etc.). When introduced into a target cell together with an sgRNA, such fused Cas9 enzymes modify epigenetic information, such as DNA methylation, histone acetylation, etc., instead of or in addition to cleaving or replacing dsDNA sequences.
[0037] In one aspect of using RNA to provide sgRNA, the above-mentioned guide RNA, structural RNA as in the representative sgRNA, and, if necessary, linker RNA can be further fused to patch template RNA for local repair after cleavage by Cas9 enzyme. It is known in the art that RNA can be used for homologous DNA break repair (Storici et al., 2007), which is incorporated herein by reference).
[0038] In another embodiment, DNA or RNA aptamers that specifically bind to Cas9 are linked to sequence replacement "patch" templates to achieve gene knock-in or knock-out through the use of template polynucleotides. By being physically linked to the Cas9 enzyme, the patch can be delivered near the site of CRISPR / CAS cleavage. The patch template can be either DNA or RNA.
[0039] One important embodiment of the present disclosure relates to delivering cas mRNA and sgRNA at appropriate absolute and relative doses. One of the unique advantages of using RNA as a form of delivery of genetic information is that expression is more controllable than using DNA. For the expression of proteins such as enzymes, mRNA molecules do not need to be translocated to the nucleus, thereby eliminating the bottleneck and multiple uncertainties regarding the molar ratio between DNA and mRNA that are typically presented by entering the nucleus. The Cas proteins can be highly expressed immediately after the encoding mRNA enters the cytoplasm by transfection or electroporation process. In addition, it is also beneficial that the control of the off-target effects of the CRISPR / CAS system is more manageable than using DNA or viral vectors, since RNA molecules have a relatively short half-life by nature.
[0040] A further embodiment of the present disclosure regarding dosing control relates to adjusting the ratio between gRNA Cas and mRNA. Since the dose of cas9 mRNA can be essentially proportionally correlated to the level of Cas enzyme, the all-RNA CRISPR / Cas system disclosed herein allows for direct matching between the two components of CRISPR / Cas, i.e., Cas enzyme and gRNA, to obtain the highest on-target and lowest off-target DNA cleavage. EXAMPLES
[0041] Example 1 - Generation of cas9 IVT template DNA encoding Cas9 derived from the bacterium Streptococcus pyogenes was codon-optimized for optimal expression in mammalian, and specifically human, cells. The complete gene was assembled from three fragments generated through a commercial gene synthesis service (Gene Oracle); mutations that disrupt the DNA endonuclease domain were included during gene synthesis to obtain the different versions of cas9 as set forth in SEQ ID NOs: 1-4.
[0042] Example 2 - Generation of cas9 mRNA Synthetic mRNA was generated in IVT reactions using a 4:1 ratio of anti-reverse cap analog (ARCA) to GTP to generate a high percentage of capped transcripts. 20% 5m-CTP instead of CTP and 2-thio-UTP instead of UTP were used in the nucleotide triphosphate (NTP) mix to reduce the immunogenicity of the RNA product. ARCA and modified NTPs were purchased from Trilink Biotechnologies (San Diego). A 2.5x NTP mix was prepared (ARCA:ATP:GTP:C:5m-CTP:UTP:pseudoUTP at 15:15:3.75:3:0.75:3:0.75 mM). Each 20 μL IVT reaction contained 8 μL NTP mix, 2 μL 10x T7 buffer, 8 μL DNA template, and 2 μL T7 enzyme (Promega). Reactions were incubated at 37°C for 4-6 hours and then treated with 1 μL RNase-free DNase for an additional 30 minutes at 37°C before purification on a spin column and eluting the RNA product in a volume of 80 μL. 8 μL 10x PAP buffer and 8 μL 10 mM ATP and 2 μL PAP (NEB) were added for 10 minutes to add a poly(A) tail, followed by 3 μL Antarctic phosphatase (New England Biolabs) for 10 minutes to remove immunogenic 5' triphosphate moieties from uncapped transcripts and 10 μL reaction buffer. Phosphatase reactions were incubated at 37°C for 30 minutes and the IVT products were repurified if necessary (Figure 2).
[0043] Example 3 - Generation of sgRNA by IVT Synthetic sgRNAs were generated in IVT reactions using a 4:1 ratio of ARCA cap analog to GTP to generate a high percentage of capped transcripts. 20% 5m-CTP instead of CTP and 2-thio-UTP instead of UTP were used in the nucleotide triphosphate (NTP) mix to reduce the immunogenicity of the RNA product. Cap analogs and modified NTPs were purchased from Trilink Biotechnologies. A 2.5x NTP mix was prepared (ARCA:ATP:GTP:C:5m-CTP:UTP:PseudoUTP at 15:15:3.75:3:0.75:3:0.75 mM). Each 20 μL IVT reaction contained 8 μL NTP mix, 2 μL 10x T7 buffer, 8 μL DNA template, and 2 μL T7 enzyme (Promega). Reactions were incubated at 37°C for 4-6 hours and then treated with 1 μL RNase-free DNase for an additional 30 minutes at 37°C before purification on a spin column and the RNA product was eluted in a volume of 80 μL. 3 μL Antarctic phosphatase (New England Biolabs) was added for 10 minutes to remove immunogenic 5' triphosphate moieties from uncapped transcripts and 10 μL of reaction buffer. Phosphatase reactions were incubated at 37°C for 30 minutes and the IVT products were repurified if necessary (Figure 2).
[0044] Example 4 - Modification of reporter genes in human cells To demonstrate the utility of the disclosed system, a complete all-RNA CRISPR / CAS system was created to disrupt the fluorescent protein (FP) mWasabi (Allele Biotech) permanently expressed in mammalian cells NIH-3T3. NIH3T3-mWasabi cells were grown at 15% confluency in serum-free medium and cas9 mRNA and sgRNA were co-transfected into the cells; after 2 hours, serum-containing medium was added. As illustrated in Figure 3, from left to right, cells received 0 ng, 0.2 ng, or 0.8 ng of sgRNA against the mWasabi site nt43 (W43), as indicated below each panel. The top panel shows cells present (phase contrast); the bottom panel shows cells that are still fluorescent (green fluorescent channel). The three arrows in the bottom right panel point to cells that have lost green fluorescence in wells that received a higher dose of sgRNA together with cas9 mRNA. None of the cells in the 0 ng or 0.2 ng sgRNA wells lost green fluorescence.
[0045] Example 6 - Method embodiment for generating single base pair mutations via mRNA-based CRISPR / Cas9 system A. Sequence Design: I. Exemplary Method Embodiments for sgRNA Sequence Design:
[0046] 1) A 300bp sequence around the intended mutation site is run through a web-based sgRNA design tool ("MIT Crispr Design Tool" MIT). 2) Guide RNA selection is determined by two parameters: a) proximity to the intended mutation, and b) potential off-target score. 3) A minimum of two sgRNA sites are selected (optimal parameters are a PAM site within 5bp of the intended mutation and an sgRNA score >70).
[0047] II. Exemplary Method Embodiments for Designing Single-Stranded Oligonucleotide Donor (ssODN) Repair Templates:
[0048] 1) Obtain 60-100 bp sequence with homology arms centered on the intended mutation. 2) Optional: engineer a silent mutation to disrupt a protospacer adjacent motif (PAM) site (i.e., from NGG to NGT, NGA, or NGC). 3) Optional: engineer a silent mutation <10 bp away from the intended mutation to create a restriction site. This may facilitate the screening process. 4) Obtain ssODN via IDT "Ultramer:" service (standard desalting 4 nmol) (Integrated DNA Technologies, Coralville, Iowa).
[0049] III. Exemplary Method Embodiments for Genomic DNA Amplification:
[0050] 1) BLAST search the genomic region for pseudogenes or other highly similar genomic sequences. 2) Design and test a large set of primer pairs to amplify a ~400-600 bp region centered around the intended mutation using genomic DNA lysate templates. 3) Select the best primer pair to screen CRISPR-treated cells based on the strength of amplification (i.e., high yield and absence of nonspecific bands). 4) Sequence the PCR products to verify the quality of the sequencing reads of the amplicons.
[0051] IV. Exemplary primers for qPCR-based screening:
[0052] 1) The Tm of the qPCR primers are selected to be approximately 64° C. 2) The forward primer may be approximately 100 bp away from the intended mutation and may be included within the amplicon generated from step III. 3) The reverse primer (mutation specific) may have the intended mutation at its 5′ end.
[0053] B. Exemplary Method Embodiments for In Vitro Transcription (IVT) of sgRNA and Cas9 Wt mRNA I. Regarding IVT template generation of sgRNA: 1) Design and synthesize a forward primer with the following three elements: a) T7 promoter, b) protospacer element sequence (step AI2), and c) crRNA-specific sequence. Use a universal reverse primer (sgRNA_Rev) to complete the primer pair. 2) Use these primers and the pT7sgRNA plasmid as a template to perform a PCR reaction to generate the IVT template (approximately 131 bp). DpnI digest the reaction sample and perform PCR cleanup as may be suitable for in vitro transcription reaction.
[0054] II. An exemplary method embodiment for generating IVT template for Cas9wt. 1) Using pIVT-Cas9wt plasmid as template and INS-F+d(T)120-Rev as primer pair, PCR reaction is performed to generate IVT template. 2) PCR cleanup is performed on the resulting PCR product to be suitable for in vitro transcription.
[0055] III. Exemplary method embodiment for IVT reaction to generate CRISPR elements. 1) Using templates generated via PCR, IVT reaction is performed to transcribe sgRNA and Cas9wt mRNA. 2) QC transcripts are purified via gel imaging and Bioanalyzer (Agilent).
[0056] IV. An exemplary embodiment of a method for validating IVT sgRNAs via in vitro cleavage testing. 1) A cleavage template for validating IVT-transcribed sgRNAs is created by amplifying a fragment of genomic DNA containing the target sequence (created in step A.III.3). 2) The cleavage reaction of the cleavage template is performed using the sgRNA from B.III.1 in combination with recombinant Cas9 nuclease (see protocol III below). 3) Cas9 and sgRNA are complexed in a 1:1.2 ratio, respectively. 4) The RNP complex is incubated with the cleavage template amplicon in a 10:1 ratio, and the reaction is then run on an agarose gel. 5) The gel is analyzed to evaluate the cleavage efficiency by observing low molecular weight cleavage bands.
[0057] C. Exemplary Method Embodiments for qPCR SYBR Green-Based Screening I. Construction of plasmids and amplicon standards: 1) Subclone the region of interest (amplified from genomic DNA template using pIVT-compatible overlapping primers) into the pIVT vector via Gibson assembly. The insert is between 400-600 bp. This is referred to as the "WT" vector. 2) Use the QuickChange site-directed mutagenesis kit (Agilent) to generate the intended single point mutation (follow the kit's instructions for designing the mutagenic primers and for thermal cycling parameters). The resulting construct is referred to as the "mutated" vector. 3) Amplify the "WT" and "mutated" constructs with the primers designed in A.III to generate the "WT" and "mutated" amplicons. Optional: Sequence the purified PCR products by Sanger method to confirm the WT and mutated sequences. 4) Quantify the amplicons using a Nanodrop spectrophotometer and then standardize the concentrations by diluting the amplicons down to 60 fg / μl, respectively. After standardization of concentrations, assemble in the following ratio: 0% "Mutation", 100% "WT" 1% "mutation", 99% "WT" 10% "mutation", 90% "WT" 50% "Mutation", 50% "WT"
[0058] II. Exemplary method embodiment for assaying standards with qPCR: 1) Set up a qPCR plate with: a) Template: Standards (including duplicates) made in step Ib) Primers: Use the primers designed in A.IV. 2) Run a standard quantitative RT-PCR program with SYBR green reporter and compare the Ct values of each standard point. The Ct values reflect the relative mutant population ratio (higher mutant ratios result in lower Ct values). 3) The 1% "mutated" standard has a delta Ct of about ≧2 when compared to 100% "WT". With a delta Ct of ≧2, the qPCR-based screening method can reliably detect mutations with a sensitivity of at least 1%. D. Exemplary Method Embodiments for Transfection of Target Cells (iPSCs)
[0059] I. Plate exemplary target cells: 1) Cells are cultured in E8 medium supplemented with ROCK inhibitor (Y27632) during passaging. 2) The day before transfection, cells are plated at 2.5×10 5 Passage into 6-well plates at a density of cells / well.
[0060] II. Exemplary method for transfection of CRISPR elements: 1) The day after seeding, the cell density is at least doubled, showing small clusters of 1-4 cells. 2) Transfect the cells with the IVT RNA CRISPR elements generated in B.III.1 and the ssODN ordered in A.II.4 using Messenger Max transfection reagent. In addition, perform a negative control transfection containing only the ssODN. To measure transfection efficiency, the negative control should also contain 100 ng mRNA encoding a fluorescent protein (e.g., mNG). 3) 4 hours after transfection, replace the transfection medium with fresh pre-warmed E8 medium (supplemented with Y27632). 4) The next day (approximately 12-18 hours later), check mNG expression in the negative control wells. If expression is strong, proceed with a second transfection of sgRNA and ssODN in the experimental and negative control wells. Cas9 mRNA can be delivered repeatedly in a repeat transfection. 4 hours after the repeat transfection, the transfection medium is replaced with fresh E8 (with Y27632). 5) The cells are cultured for another 2 days and then passaged into another 6-well plate at a 1:3 dilution. The remaining cells are lysed and analyzed.
[0061] E. Exemplary Method Embodiments for Screening and Cloning CRISPR Treated Cells I. Exemplary method embodiment for lysis of treated cells and amplification of gDNA for screening. 1) Perform lysis of remaining cells from D.II.5 experimental and negative control wells. Resuspend cells in Allele's Mouse Tail lysis buffer (Allele Biotech, San Diego) and run samples using the lysis program on a thermocycler. Amplify the resulting lysate (<26 cycles) using primers designed in A.III.3 with Herculase II fusion DNA polymerase (Agilent Technologies). Perform PCR cleanup on PCR products. The resulting experimental and negative control amplicon libraries are referred to as the experimental and negative control "bulk populations". 2) Quantify PCR products using Nanodrop as above and perform dilutions to normalize all amplicons to 60 fg / μl.
[0062] II. Exemplary method embodiment for screening bulk population: 1) Perform SYBR green-based standard quantitative qPCR screening with the bulk amplicon library generated in the previous step and the standard generated in CI4. 2. If the ΔCt between the experimental library and the negative control library is ≧2 and within the 1% mutant population according to the standard, proceed to the single cell cloning step. See Figure 7.
[0063] III. Exemplary method embodiment for single cell 96-well plate passaging: 1) From CRISPR experimental cells at passage 2, dissociate cells using TrypLE. Pass cells through a 70 μm cell strainer to generate a single cell suspension, then determine cell number and calculate dilution resulting in 2-3 cells / 100 μl; 2) Seed 2-3 cells / well (100 μl / well) in pre-warmed E8 (supplemented with Y27632) into 4 Matrigel-coated 96-well plates; 3) Quickly check the presence of attached cells by microscopy the next day. Wells should have between 0-3 cells / well (not necessary to check all wells). Perform half-volume medium changes once a day (aspirate 50 μl and add 50 μl pre-warmed E8 supplemented with Y27632); 4) after proliferation to approximately 50-100 cell clusters is established (typically, about 7 days), switch to E8 not supplemented with Y27632 and change the medium every 2 days.
[0064] IV. Exemplary method embodiments for generating replicate plates for screening: 1) Once the cells reach >70% confluence, passage 1 / 4 of the cells into Y27632-supplemented E8 medium with EDTA onto a new Matrigel-coated 96-well plate. The resulting plate is called the "duplicate plate." Place the remaining 3 / 4 of the cells in the original plate with fresh pre-warmed Y27632-supplemented E8 medium (cells will reattach). 2) Replace medium with Y27632-supplemented E8 once a day for both the duplicate and original plates. After 3-5 days, the original plate should be ready for lysis and analysis.
[0065] V. Exemplary method embodiment for screening of clone plates: 1) Perform lysis protocol (same as EI1) on original plate. Test PCR is performed in 3 wells with 2 lysate volumes to identify optimal lysate template volume. 2) Perform plate PCR of cell lysate of original plate. Once PCR is completed, run PCR products of the plate on a large format agarose gel to confirm amplification and provide a record of any variation in amplification yield. 3) Purify PCR products using SurfaceBind Purification Plate (Allele Biotech) according to protocol. Elute in 30 μl elution buffer. 4) Make 1:1000 dilution of purified PCR products into molecular grade water. Use 2 ml collection plate to maintain plate format. The amplicon library is now at a suitable concentration for screening. 5) Perform SYBR green based standard quantitative qPCR screening on amplicon library of four 96 well plates. Optionally: Include a positive control (1% mutant standard library) and a negative control (use a negative control amplicon library) in any well positions that correspond to empty wells in the plate (i.e., where cells did not attach / grow). 6) The left-most qPCR Ct curve (the "outlier") represents the well with the highest probability of containing a mutant cell population (i.e., with the intended HDR event). Perform Sanger sequencing analysis on the original purified amplicon library stock that matches all outlier wells.
[0066] VI. Exemplary embodiment of the method for clonal selection and expansion: 1) Analyze the EV6 sequencing results to confirm the presence of the intended mutations and determine the relative size of the mutant population (i.e., in the case of a mixed population) based on the ratio of peaks in the chromatogram. Expand the confirmed outlier wells by passaging from the duplicate plate made in E.IV.1. In the first expansion, passage one well from the 96-well plate to one well in a 12-well plate. a) If the sequencing results indicate a mixed population, perform a second round of single cell cloning (repeat steps starting from E.III). When cells are confluent (approximately 10 5 Once the population reaches 100,000 cells, expand and freeze the confirmed outliers and proceed to a second round of single cell cloning. Recommendation: Lyse, amplify and sequence any remaining cells to test whether the mutation is preserved after passaging. b) If the sequencing results indicate a pure population (i.e., the ratio of chromatogram peaks corresponding to WT and Mutant is 1:1 [indicating a heterozygous population]), confirm that the cells are heterozygous by performing a second analytical round of single cell cloning by analyzing 24-48 wells. Expand the cells to a 6-well plate format. Resuspend the cells in 10 mL of 10 mL of 10% PBS. 6 Cryopreserved at a concentration of 1000 cells / vial. A portion of the cells are lysed, amplified and sequenced to test if the mutation has been preserved after passaging.
[0067] Protocol I. Exemplary Method Embodiments for Purification of sgRNA IVT Templates Materials: - pT7sgRNA plasmid; sgRNA reverse primer; custom sgRNA forward primer; 10mM dNTPs; Phusion polymerase (New England Biolabs) with 5x GC buffer; DpnI restriction enzyme; NucleoSpin® gel (Clontech) and PCR cleanup; molecular grade H2O; 1% agarose gel / 1x TAE running buffer; Bioline 1kb DNA ladder. The PCR reaction is assembled as per Table 1 below: [Table 1] After assembly, run the program as shown in Table 2. [Table 2] 2) Run 2 μl of the PCR product on a 1% agarose gel with a 1 Kb DNA ladder to confirm yield and correct size of 131 bp. 3) Add 1 μl of DpnI enzyme directly to the PCR reaction and incubate at 37° C. for 15 minutes to digest the template plasmid. 4) Perform PCR cleanup using the NucleoSpin kit according to the manufacturer's protocol. 5) The template is ready for the in vitro transcription reaction.
[0068] II. Exemplary Method Embodiments for IVT Template Generation of Cas9WT material: -pIVT-Cas9WT plasmid -Tail 120 reverse primer -Insert-F forward primer -KAPA Biosystems' HiFi HotStart ReadyMix -NucleoSpin® gel and PCR cleanup -Molecular Grade H2O -1% agarose gel / 1x TAE running buffer -Bioline 1kb DNA Ladder 1) Assemble the PCR reaction as per Table 3 below: [Table 3] 2) 2 μl of the PCR product is run on a 1% agarose gel alongside a 1 Kb DNA ladder to confirm yield and correct size of approximately 4.5 kb. 3) Perform PCR cleanup using the NucleoSpin kit according to the manufacturer's protocol. 4) The template is ready for the in vitro transcription reaction.
[0069] III. Exemplary Method Embodiments for Expression of Recombinant Cas9 material: -pCold-Cas9Wt plasmid -SOC medium -2XYT medium -Carbenicillin -LB-Agar Plate -NEB Express Competent Cells -1M IPTG -High density cobalt resin -Coupling Buffer (100 mM phosphate, 150 mM NaCl) -Lysis buffer (50mM NaPO4, 300mM NaCl, 5mM Imidazole) -Elution buffer (100mM NaPO4, 150mM NaCl, 200mM Imidazole) -Dialysis buffer (300mM NaCl, 10mM Tris-HCl pH8.0, 0.1% Tween) a) Bacterial expression: 1) Transform the E. coli host strain (NEB Express) with the pCold-Cas9Wt plasmid and select for transformants on LB-carbenicillin selection plates. 2) The transformant is inoculated into 5 ml of medium (containing 100 μg / ml of carbenicillin) and cultured at 37° C. with shaking for 24 hours. 3) The next day, add 5 ml of the growing culture to a large 2.5 L flask with 500 ml 2XYT-Carb. At OD600=0.4-0.5, quickly cool the culture to 15°C and let stand for 30 minutes. 4) IPTG is added to a final concentration of 0.1-1.0 mM and the culture is continued for 24 hours with shaking at 15°C. 5) Remove the overnight cultures from the shaking incubator. 6) Pour the culture into a clean Oakridge tube. 7) For cultures of 500 mL or larger, half of the culture can be poured into a tube. 8) Centrifuge the Oakridge tubes in a Sorvall centrifuge at 5,000 g for 10-15 minutes at room temperature. 9) Ensure that the seam of the Oakridge tube does not face the center of the rotor to avoid breaking the tube. 10) The supernatant is decanted from the tube when centrifugation is complete. 11) If working with larger cultures, repeat the previous 3 steps. B. Cell lysis 1) The pellet present in the Oakridge tube is suspended by adding 25 mL of lysis buffer and gently swirling. 2) Once the pellet is completely resuspended, pour the resuspension into a 50mL ultra-performance tube. 3) Bring the volume of the 50 mL tube up to 50 mL using lysis buffer. 4) Divide this 50mL volume into two 50mL ultra-performance tubes (25mL each). 5) Place both tubes in the freezer (-20) until completely frozen (or for long term storage), which usually takes 1-3 days. 6) Remove the tube from the freezer and allow to thaw completely. 7) Add a few drops (2-3) of antifoaming agent. 8) Place the tube on ice and sonicate for up to 3 minutes. *Note that the sonicator probe does not touch the bottom of the tube, but is fairly close to it. 9) Place the tube in an Eppendorf centrifuge and centrifuge for 15 minutes at 4° C. and maximum speed. 10) Ensure that the centrifuge is properly balanced. 11) While the tube is being centrifuged, pour approximately 5 mL of the cobalt slurry into a sterile 50 mL tube. 12) Add 20 mL of lysis buffer to the cobalt slurry. 13) When the cobalt resin has settled to the bottom, pour off the lysis buffer. 13) Once the centrifugation is complete, filter the lysate (supernatant) using a 0.7 μm syringe filter and add it to the cobalt resin. 14) Tumble at 4°C for 10 to 30 minutes. c. His-tag purification 1) Pour the protein / cobalt slurry into a drip column and allow it to drain completely. It is not necessary to retain the flow-through or any subsequent washes. 2) Wash the 50 ml tube that previously contained the protein with 15 ml of lysis buffer. 3) Pour this wash into the drip column. 4) Wash the column with 10-15 mL of coupling buffer. Allow it to drip. 5) Place a sterile 15ml collection tube under the column. 6) Pour 15 ml of elution buffer onto the column and collect the eluted protein in the tube. 7) Measure the protein concentration and store at 4° C. until needed. D. Dialysis 1) Filter the protein with a 0.45 μm syringe filter into a 30 kD spin column filter unit. Add dialysis buffer (if necessary) to the filter unit to bring the total volume to 15 mL. 2) Place the filter unit in a centrifuge (swinging bucket rotor) and centrifuge at 4000 g for 20 minutes at room temperature or until the volume remaining in the filter unit is 1 mL or less. 3) Remove the filter unit from the centrifuge. Discard the flow-through. Add an appropriate amount of dialysis buffer to bring the total volume back to 15 mL. Mix by inverting the filter unit. 4) Repeat until a dilution factor of at least 4,000 is achieved. The dilution factor can be calculated as follows: df=(Vfinal / Vinitial).
[0070] IV. Exemplary Method Embodiments for In Vitro Transcription of sgRNA and Cas9WT material: -Anti-reverse cap analog, ARCA -2-Thio-UTP -5-Methyl-CTP -rATP -rUTP -rGTP -rCTP -T7 RNA polymerase -Transfer Optimized 5x Buffer -DTT 100mM -1M MgCl2 solution -RQ1 RNase-free DNase -Antarctic phosphatase -10× Antarctic Phosphatase Reaction Buffer -TE buffer pH=8.0 -RNA Clean & Concentrator TM -twenty five -TE buffer pH=7.0 1) IVT reactions are assembled as per Table 4 below: [Table 4] 2) NOTE: Add template DNA to a PCR tube before adding it to a 1.5 ml sterile microcentrifuge tube. Place the PCR tube in a PTC-100 Programmable thermal controller pre-warmed to 37°C. Using a P200 pipette, transfer 32 μl of ready-to-use master mix to each reaction. Pipette up and down 5 times to mix wells. 3) The mixture is incubated for 4-6 hours at 37°C in a T100 Thermal Cycler. 4) After performing the in vitro transcription reaction as completed in step 8.2.3, add 2 μl of RQ1 RNase-free DNase is added to each reaction to remove the DNA template. 5) Incubate the above mixture for at least 30 minutes in a T100 Thermal Cycler at 37° C. After the incubation period in step 5.2.5 is over, add 5 μl of 10× Antarctic Phosphatase Reaction Buffer and 3 μl of Antarctic Phosphatase to each reaction. 6) Incubate the above mixture for at least 30 minutes at 37° C. in a Thermal Cycler. 7) After the incubation in step 7 is complete, check the mRNA by E-gel. i) For each sample, add 9 μl of TE buffer pH=8.0 with 1 μl of prepared mRNA into a separate PCR tube using a P20 pipette and an appropriately sized tip. Using the same tip, gently swirl the contents of the tube to mix. ii) Proceeding, 10 μl of each mixture is loaded into each well on an E-gel. Each sample occupies one well. iii) Run the built-in program of the E-gel electrophoresis system for 8 minutes. For the operation of the equipment, refer to the E-gel iBase Power System Equipment Manual. iv) Check the RNA bands with LED light. Determine if clear RNA bands appear at the correct size positions: Cas9 size: about 4400nt; sgRNA size: about 150nt. v) If a single clear RNA band is observed at the correct size position, proceed to step 8. 8) The above mRNA was purified using RNA Clean & Concentrator TM Purify at -25 according to the manufacturer's protocol. 9) RNA products are quantified by Nanodrop. Cas9WT mRNA and sgRNA are now ready for downstream use.
[0071] V. Exemplary Method Embodiments for iPSC Culturing material -TeSR TM -E8 TM - Corning® Matrigel® -Tissue culture treated cultureware -DPBS -Y-27632 (ROCK inhibitor) -PRG-1 EDTA -TrypLE 1X -Costar TM Sterile disposable reagent containers -Tissue culture grade 96-well plates -Mr. Frosty(Thremo Scientific) -DMSO -HSA -Opti-MEM -MessengerMax transfection reagent (Thermo Fisher Scientific) a.) Thawing iPSCs 1) At least 1 hour prior to thawing, coat one well of a 6-well plate with Corning® Matrigel® (1 mL / well using a 1:80 dilution in DMEM); 2.) 2ml TeSR with 10μM Y27632 TM -E8 TM Pre-warm in a 5% CO2 / 5% O2 cell culture incubator for 30 minutes. 3.) Remove one vial of iPS cell line from the LN tank or -80°C storage location. 4.) Immediately thaw the vial of cells in a 37°C water bath; 5.) Rinse the vial thoroughly with 70% ethanol and place the vial in a cell culture hood; 6.) Drop the cells into 10ml Dulbecco's Phosphate Buffered Saline (DBPS) containing calcium and magnesium in a 15ml tube; 7.) Centrifuge at 200g for 2 minutes at room temperature; 8.) Rinse the tube thoroughly with 70% ethanol and place the vial in a cell culture hood; 9.) Remove the supernatant and add 2 ml pre-warmed E8 media with 10 μM Y27632 and gently pipette up and down to resuspend the cells. 10.) Add 2ml cell suspension to one well of a Matrigel coated plate and gently tap the plate to mix the cells. 11.) Label the plate with the cell line name and passage. Place the flask in a 37°C 5% CO2 5% O2 cell culture incubator; 12.) Change the medium every other day (replenish with medium with 10 µM Y27632 until the colony size exceeds 50-100 cells). b.) Passaging (6-well plates) 1.) At least 1 hour prior to passaging, coat tissue culture treated plates with Corning® Matrigel® (1 mL / well using a 1:80 dilution in DMEM). 2.) Enough TeSR TM -E8 TM(StemCell Technologies) is aliquoted (2 mL / well in a 6-well plate) and warmed to room temperature (15-25° C.). 3.) The cells were then treated with Ca 2+ and Mg 2+ Wash with 1 mL of phosphate-buffered saline (PBS) without sucrose and aspirate. NOTE: It is not necessary to remove areas of differentiated cells. 4.) Add 0.3 mL of PRG-1, then aspirate off most of the PRG-1 within 15 seconds, leaving approximately 80 μL in the well (so that the colonies are exposed to a thin layer of liquid). 5.) Incubate at 37°C for 3-5 minutes. 6.) Gently tap the plate to aid in detachment. Add 1 mL of TeSR TM -E8 TM Add the following. 7.) Detach the colonies by gently pipetting. Take 50-250 μl of the cell / media mixture and seed into a new Matrigel-coated 6-well plate. Add 2 ml of Y27632-supplemented TeSR TM -E8 TM is added to the seeded wells. 8.) Place the plate in a 37°C, 5% CO 2 5% O 2 Place inside a cell culture incubator. Change the medium every other day (replenish with medium with 10 µM Y27632 until the colony size exceeds 50-100 cells). c.) Passage one cell (96-well plate) 1.) At least 1 hour prior to passaging, coat a new 96-well plate with Corning® Matrigel® (50 μl / well using a 1:80 dilution in DMEM). 2.) Enough TeSR TM -E8 TM Aliquot into aliquots and warm to room temperature (15-25° C.). Approximately 12 ml of TesR-E8 is required for each 96-well plate. 3.) The cells were then treated with Ca 2+ and Mg 2+Wash with 1 mL of phosphate-buffered saline (PBS) without CO and aspirate. 4.) Add 0.4 mL of TrypLE (to dissociate a single cell) and aspirate within 15 seconds, so that the colony is exposed to a thin layer of liquid. 5.) Incubate at 37°C for 3-5 minutes. 6.) Gently tap the plate to aid in detachment. Add 2 mL of Y27632-supplemented TeSR TM -E8 TM Add and pipette up and down. Pipette up the cells and strain them using a 37 μm cell strainer into a 15 ml conical tube. 7.) Perform a cell count using a Moxi Z cell counter and a Moxi Z cassette by pipetting 75 μL of the cells from step 6 into the load port of the cassette. Reading is in cells / mL. 8.) In most cases, the cell count should be between 300,000 and 500,000 cells / ml. Perform serial dilutions to obtain Y27632-supplemented TeSR. TM -E8 TM Obtain a concentration of 2-3 cells / 100 µL. 9.) After 24 hours, check the wells for single cells. 10.) Remove 50 μl of medium and add 50 μl of fresh Y27632-supplemented TeSR until approximately 50-100 cell colonies are formed (usually 7 days). TM -E8 TM Perform half-volume medium changes once a day by adding 100% Y27632. Proceed with full medium changes (without Y27632) every other day until 80% confluent. Plates are now ready for replication. d.) Duplicate plates (96-well plates) 1.) At least 1 hour prior to passaging, coat a new 96-well plate with Corning® Matrigel® (50 μl / well using a 1:80 dilution in DMEM). 2.) Enough TeSR TM -E8 TMAliquot into medium and warm to room temperature (15-25° C.). 20 ml of medium is required for each 96-well plate replicate. 3.) The cells were then treated with Ca 2+ and Mg 2+ Wash with pH 8.0-free phosphate buffered saline (PBS) (100 μl / well) and aspirate. 4.) Add 50 μl of PRG-1 EDTA to each well and aspirate 40 μL so that the colonies are exposed in a thin layer of liquid. 5.) Incubate at 37°C for 3-5 minutes. 6.) During incubation, add 75 μl Y27632-supplemented TeSR TM -E8 TM Add to each well of the replicate 96-well plate prepared in step 1. 7.) Gently tap the plate to aid in detachment. Add 125 μl of Y27632-supplemented TeSR TM -E8 TM Add and pipette up and down. 8.) Pipette 25 μl of the 125 μl detached cells into a duplicate 96-well plate. Ensure that the orientation of the plate is preserved. The original and duplicate plates should now both have 100 μl of medium. 9.) Place plates into a low oxygen incubator. Full media changes should be performed every other day until the original plates are ready to be thawed and analyzed. e.) Well / clone expansion 1.) At least 1 hour prior to passaging, coat new 12-well plates with Corning® Matrigel® (0.5 ml / well using a 1:80 dilution in DMEM). 2.) Enough TeSR TM -E8 TM Divide into aliquots and warm to room temperature (15-25°C). 3.) Selected wells were then incubated with Ca 2+ and Mg 2+ Wash with pH 8.0-free phosphate buffered saline (PBS) (100 μl / well) and aspirate. 4.) Add 50 μl of PRG-1 EDTA to each well and aspirate 40 μL so that the colonies are exposed in a thin layer of liquid. 5.) Incubate at 37°C for 3-5 minutes. 6.) Gently tap the plate to aid in detachment. Add 100 μl of Y27632-supplemented TeSR TM -E8 TM Add and pipette up and down. 7.) Pipette all 100 μl of the cell media mixture into the 12-well plate prepared in step 1. Add an additional 1 ml of Y27632-supplemented TeSR TM -E8 TM Label the wells with the appropriate source. 8.) Change the medium completely every other day until the cells are 80% confluent. 9.) Split cells into 6-well plates following the protocol outlined in Vb. These cells can be advanced to cryopreservation when confluent. f.) Cold storage 1.) Enough TeSR TM -E8 TM Divide into aliquots and warm to room temperature (15-25°C). 2.) The cells were then treated with Ca 2+ and Mg 2+ Wash with 1 mL of phosphate-buffered saline (PBS) without CO and aspirate. 3.) Add 0.3 mL of PRG-1 and then aspirate off most of the PRG-1 within 15 seconds, leaving approximately 80 μL in the well (so that the colonies are exposed to a thin layer of liquid). 4.) Incubate at 37°C for 3-5 minutes. 5.) Gently tap the plate to aid in detachment. 2+ and Mg 2+ Add 3 mL of phosphate buffered saline (PBS) containing: 6.) Detach the colonies by gently pipetting. Transfer the cells to a 15 ml conical tube. 7.) Centrifuge at 300 x g for 3 minutes at room temperature to pellet cells. Aspirate PBS. 8.) Place the pellet in cryopreservation medium (TeSR supplemented with Y27632) TM -E8 TM , 10% HSA, and 10% DMSO) resulting in concentrations ranging from 1 to 0.5 × 10 6 cells / ml. 9.) Transfer 1 mL of cell aggregates to a labeled cryovial. 10.) Freeze the cell aggregates in a -80°C freezer using Mr. Frosty followed by long term storage at -135°C (liquid nitrogen) or lower. Short term storage (<3 months) at -80°C is appropriate. g.) Passaging for transfection 1.) One day prior to transfection, seed 250,000 cells / well into Matrigel-coated 96-well plates according to the following protocol: i. At least 1 hour prior to passaging, coat new 6-well plates with Corning® Matrigel® (1 ml / well using a 1:80 dilution in DMEM). ii. Sufficient TeSR TM -E8 TM Divide into aliquots and warm to room temperature (15-25°C). iii. The cells were then treated with Ca 2+ and Mg 2+ Wash with 1 mL of phosphate-buffered saline (PBS) without CO and aspirate. iv. Add 0.4 mL of TrypLE (to dissociate a single cell) and aspirate within 15 seconds, so that the colony is exposed in a thin layer of liquid. v. Incubate at 37°C for 3-5 minutes. vi. Gently tap the plate to aid in detachment. Add 2 mL of Y27632-supplemented TeSR TM -E8 TM Add 100 ml of PBS and gently pipette up and down. Strain the cells using a 37 μm cell strainer into a 15 ml conical tube. vii. Cell counts are performed using a Moxi Z cell counter and a Moxi Z cassette. viii. Using a known cell number, add an appropriate volume of cells so that 250,000 cells are seeded per well. Add an appropriate amount of Y27632-supplemented TeSR TM -E8 TM to bring the well volume up to 2 ml. 2.) After 12-18 hours, the cells should be in small 2-5 cell clusters. The cell density should be around 70-80% before transfection. h.) Transfection 1.) Equilibrate MessengerMAX Transfection Reagent and 5ml of Opti-MEM at room temperature for 10 minutes. 2.) Assemble the transfection complex according to Table 5: [Table 5] 3.) Incubate the diluted MessengerMax for 10 minutes and then mix with the diluted mRNA according to Table 6: [Table 6] Dilute ssODN according to Table 7. [Table 7] Mix the diluted mRNA and MessengerMax transfection reagent as per Table 8 below: [Table 8] The complex is incubated for 5 minutes. 4.) The medium is removed from the two wells to be transfected and the cells are incubated with Ca 2+ and Mg 2+ Wash with 1 mL of phosphate-buffered saline (PBS) without CO and aspirate. 5.) Add the transfection complex mixture to each well. Set up the plate as per Table 9 below: [Table 9] 6.)Y27632 Replenishment TeSR TM -E8 TM is added to each well for a final volume of 600 μl. The plates are placed in a low oxygen incubator. 7.) After 4-6 hours, aspirate the transfection medium and replace with 2 ml Y27632-supplemented TeSR. TM -E8 TM Allow cells to incubate overnight. 8.) After 12-18 hours (or the following morning), confirm that the transfection was successful by checking mNG fluorescence, then proceed to the second transfection (sgRNA and ssODN only). 9.) Second Transfection: Prepare the transfection complexes according to Tables 10-13 below: [Table 10] The diluted MessengerMax is incubated for 10 minutes and then mixed with the Cas9 mRNA. [Table 11] [Table 12] 10.) Mix the diluted mRNA and MessengerMax transfection reagent as per Table 13 below: [Table 13] The complex is incubated for 5 minutes. 11.) Remove the medium and inoculate the cells with Ca 2+ and Mg 2+ Wash with 1 mL of phosphate-buffered saline (PBS) without CO and aspirate. 12.) Add transfection complexes to each well. Set up the plate as per Table 14 below. [Table 14] 13.)Y27632 Replenishment TeSR TM -E8 TM is added to each well for a final volume of 600 μl. The plates are placed in a low oxygen incubator. 14.) After 4-6 hours, aspirate the transfection medium and replace with 2 ml Y27632-supplemented TeSR. TM -E8 TM Allow cells to incubate overnight. 15.) After 2 days, your CRISPR-treated cells are ready to: i. Passage / replit. ii. Analyze via RT-PCR screening to evaluate HDR efficiency. iii. Passage to single cells for clonal screening.
[0072] VI. Exemplary Method Embodiments for Cell Lysis and Genomic DNA Amplification material -D-PBS -PRG-1 EDTA -TrypLE 1X -Allele Mouse Tail Lysis buffer (150mM NaCl, 80mM Tris-HCl pH8.5, 5mM EDTA, 2.5mM MgCl2, 1% NP40, 1% Triton X100, and 4% Tween 20) -Herculase II Fusion DNA Polymerase Kit -Costar TM Sterile disposable reagent containers -Non-skirted 96-well PCR plates -AlumaSeal CS Sealing Films - Skirted 96-well PCR plates -SurfaceBind PCR Plate Purification Kit -NucleoSpin® Gel and PCR Cleanup a. Lysing the bulk cell population (6-well plate) 1.) Cells were inoculated with Ca 2+ and Mg 2+ Wash with 1 mL of phosphate-buffered saline (PBS) without sucrose and aspirate. NOTE: It is not necessary to remove areas of differentiated cells. 2.) Add 0.3 mL of PRG-1, then aspirate off most of the PRG-1 within 15 seconds, leaving approximately 80 μL in the well (so that the colonies are exposed to a thin layer of liquid). 3.) Incubate at 37°C for 3-5 minutes. 4.) Gently tap the plate to aid in detachment. Add 3 ml of phosphate-buffered saline (PBS) and gently pipette the cells up from the bottom of the plate and transfer to a 15 ml conical tube. *Optional: Passage a portion of the detached cells (>50,000 cells) to a new Matrigel-coated plate according to protocol Vb. This optional step is performed after CRISPR transfection to allow a portion of the population to be expanded while the remaining cells are lysed and analyzed. If bulk analysis indicates adequate HDR efficiency, the remaining cells upon reaching confluence can be cloned into single cells by limiting dilution (see Vc). 5.) Centrifuge at 300×g for 3 minutes at room temperature to pellet cells. Aspirate PBS. 6.) Resuspend the cell pellet in 150 μl lysis buffer. Transfer to a PCR tube and run the following program in a thermocycler: 65° C. for 15 minutes, 68° C. for 15 minutes, and 95° C. for 15 minutes: 7.) After completion of the thermocycler program, the lysate is ready to be used as a template in a PCR reaction. b.) Lysing clonal populations (96-well plates) 1.) Remove the medium and replenish the wells with Ca 2+ and Mg 2+ Wash with 100 μl phosphate buffered saline (PBS) free of each other and aspirate. 2.) Using a multichannel pipette, add 50 μl of Lysis Buffer directly to the wells. Pipette up and down 4-5 times. 3.) Transfer the lysis buffer from the cell culture plate to a non-skirted PCR plate. Seal the top of the plate with AlumaSeal. Using a thermocycler, run the following program on the plate: -65°C for 15 minutes, 68°C for 15 minutes, and 95°C: 4.) After completion of the thermocycler program, the lysate is ready to be used in the PCR reaction. c.) Amplifying genomic DNA templates from lysates 1.) In a PCR tube on ice, assemble the PCR reactions as in Table 15 below for 6-well plate lysates: [Table 15] 2.) In a non-skirted PCR plate, assemble PCR reactions as in Table 16 below for the 96-well lysates. [Table 16] 3.) Run the following PCR program, Table 17: [Table 17] 4.) After the program is completed, run 2 μl of PCR product on a 1% agarose gel to confirm amplification and evaluate amplification efficiency. If the PCR band shows weak intensity, optimization may be required (annealing temperature, and primer design). Strong amplification is required in <26 cycles before proceeding to screening. 5.) Purify PCR products from bulk lysate templates using the NucleoSpin kit according to the manufacturer's protocol. For purification of PCR products from 96-well plate lysates, use the SurfaceBind plate purification kit according to the manufacturer's protocol. 6.) The purified amplicon library is now suitable for qPCR-based screening.
[0073] VII. Exemplary Method Embodiments for In Vitro Cas9-sgRNA Cleavage Assays material: - recombinant Cas9Wt protein (from III) - In vitro transcribed sgRNA (from IV) -Cut template (amplicons generated at the sgRNA site from the lysate) -10× Cas9 nuclease reaction buffer (20 mM HEPES, 100 mM NaCl, 5 mM MgCl2, 0.1 mM EDTA) 1.) Assemble the reactions at room temperature in the order shown in Table 18 below: [Table 18] 2.) Mix thoroughly and pulse-spin in a microcentrifuge, then incubate at 37° C. for 45 minutes. 3.) Proceed with fragment analysis by running samples on a 0.5%-1% agarose gel.
[0074] VIII. Exemplary Method Embodiments for qPCR-Based Screening material -LightCycler® 480 SYBR Green I Master Mix -MicroAmp® Fast Optical 96-well Reaction Plate, 0.1mL -Gibson Assembly Master Mix -DH5α competent cells -Herculase II Fusion DNA Polymerase Kit -QuikChange Site-Directed Mutagenesis Kit -NucleoSpin® Gel and PCR Cleanup -Excel Scientific ThermalSeal® RT for Real-Time PCR TM film a.) Construction of plasmids for mutant amplicon copy number standards 1.) PCR amplify the targeted locus following the protocol outlined in VI.c. The template should be derived from a lysate of untransfected cells. In this case, the forward and reverse primers should also have a region of overlap with the pIVT vector for Gibson Assembly. Examples of primers (n=locus specific): Forward: 5'- GAGTAAGAAGAAATATAAGAGCCACCnnnnnnnnnnnnnnnnnn-3' (SEQ ID NO:5) Reverse: 5'- AGGCAAGCCCCGCAGAAGGCAGCnnnnnnnnnnnnnnnnnn-3' (SEQ ID NO:6) The pIVT vector must be linearized via PCR by using pIVT-F and R. pIVT-F: GCTGCCTTCTGCGGGGCTTGCCT (SEQ ID NO: 7) pIVT-R: GGTGGCTCTTATATTTCTTCTTACTC (SEQ ID NO: 8) 2.) Combine the insert (genomic locus amplicon) and vector (pIVT backbone) with the Gibson assembly mix. The suggested Gibson Assembly constitutes Table 19. [Table 19] The Gibson Assembly reaction is incubated for 1 hour at 50° C. and then transformed into DH5α chemically competent cells. The resulting vector is referred to as the wild-type vector. 3.) Using the newly assembled wild type vector as a template, the desired intended mutations are made and screened with the QuikChange site-directed mutagenesis kit in the region of interest. Site-directed mutagenesis is performed according to the manufacturer's (Agilent) protocol. The resulting construct is referred to as the mutant vector. 4.) Using the completed mutant and wild-type pIVT constructs, proceed to generate amplicon standards. Separate PCR reactions are assembled using the wild-type and mutant pIVT constructs as templates Table 20. [Table 20] Run the following PCR program as shown in Table 21. [Table 21] 5.) Run 1 μl of PCR product on a 1% agarose gel to confirm proper yield and correct size. Then proceed to the NucleoSpin PCR cleanup procedure according to the manufacturer's protocol. 6.) Quantitate the resulting amplicons: Make dilutions of the amplicon standards such that they are both standardized to 60 fg / μl. This corresponds to approximately 60,000 copies of amplicon per μl. 7.) Use mutant and wildtype standards diluted to working concentrations to create the following wildtype:mutant ratios (for use in qPCR assay development): Table 22. [Table 22] b.) qPCR assay development with mutant amplicon copy number standards 1.) Design the most suitable forward and reverse primer pair for screening the amplicon. Design criteria: -≦300bp product. -The forward primer should be approximately 200-300 bp upstream of the intended mutation. - The reverse primer should carry the intended mutated base at its 5' end (see Figure 6). On ice, prepare qPCR reactions in a Fast Optical 96-well reaction plate as shown in Table 23: [Table 23] NOTE: In certain embodiments, since multiple reactions are being assembled, a master mix is prepared with SYBR Green, primer pairs, and HO, and then amplicons are added. It is best to add the standard template as a last step. The amplicon standard templates are assigned in the following orientations as shown in Table 24: [Table 24] 3.) Once the plate is prepared, seal with the clear ThermalSeal and centrifuge briefly (approximately 3g, 10 seconds). Place the plate back on ice while you set up the software program. 4.) Run the software: Open the i.StepOne Plus software and log in as "GUEST". ii. Open the template file by clicking the "Template" button at the bottom left and select the "Crispr-Standards" template file. (D:\Applied Biosystems\StepOne Software v2.3\config\templates) iii. Go to the "Experiment Properties" page and fill in "Experiment Name" with an appropriate title (e.g., Crispr_standards_test12-25-18) iv. Next, go to the “Run Method” page and change the annealing temperature to the temperature most suitable for your experiment. v. Place the prepared plate into the StepOnePlus instrument and close the drawer / cover. Click the green "Start Run" button to begin the run. c.) Amplification curve analysis 1.) Compare the Ct values of the different ratios to ensure that the primer design effectively discriminates against wild type amplification. 2.) A dose response should be observed: Ct values shift to the left (smaller) as the ratio of mutant populations increases. 3.) Some suggested ΔCt values for each standard point are shown in Table 25: [Table 25] Example of amplification Ct curve (see Figure 7) 4.) If the amplicon standard produces appropriate results (as exemplified above), proceed to screening the CRISPR edited cells. d.) Bulk population screening 1.) Normalize concentration down to 60 fg / ul using the amplicon generated in step VI.c. 2.) On ice, prepare qPCR reactions in a Fast Optical 96-well reaction plate as shown in Table 26: [Table 26] NOTE: When assembling a large number of reactions, it is best to prepare a master mix with SYBR Green, primer pairs, and HO, and then add the amplicon template in the last step. 3.) Allocate amplicon standards in the orientation outlined in step VIII.b.2.A. Allocate normalized amplicon libraries from the bulk population to plates in triplicate. Be sure to include a negative control (cells transfected with ssODN only). 4.) Once the plate is prepared, seal with the clear ThermalSeal and centrifuge briefly (approximately 3g, 10 seconds). Place the plate back on ice while you set up the software program. 5.) Run the software as outlined in step VIII.b.4. Before starting, ensure that the CRISPR amplicon library and negative controls from the experiment are assigned according to how they were assigned to reaction plates in the "Plate Setup" window. When everything is set up properly, run the program. e.) Bulk Screen Analysis 1.) Using the qPCR results from VIII.d, the amplicon libraries may be compared to each other (CRISPR-treated and non-transfected cells) and to standards. The ΔCt of the CRISPR-treated cells should be calculated by taking the negative control Ct value and subtracting the Ct value of the CRISPR-treated cells. The CRISPR-treated cells should show a ΔCt comparable to the 1% standard (Note: ΔCt has been observed to increase after one passage). 2.) If the ΔCt of the bulk population is approximately 1%, proceed to the single cell cloning procedure as outlined in step V. f.) qPCR screening of clones from 96-well plates 1.) Use the SurfaceBind purified clonal amplicon library plate (as described in step VI.c.5) as a template for qPCR screening. 2.) Make a 1:1000 dilution of the clonal amplicon library in a 96-well 2 ml collection plate. Seal the plate using AlumaSeal and vortex to mix. 3.) On ice, prepare qPCR reactions as shown in Table 27 in a Fast Optical 96-well reaction plate as follows: [Table 27] NOTE: Since a large number of reactions will be performed, prepare a master mix containing SYBR Green, primer pairs, and HO, then add the diluted amplicon library last. Be sure to preserve the orientation of the plate. 4.) Once the plate is prepared, seal with the clear ThermalSeal and centrifuge briefly (approximately 3g, 10 seconds). Place the plate back on ice while you set up the software program. 5.) Run the software with the "96_well_screen" template file (D:\Applied Biosystems\StepOne Software v2.3\config\templates) as outlined in step VIII.b.4 (the "Run Setup" window and its parameters (ensuring that the meter is identical to that in the bulk qPCR screen assay). g.) Analysis of clonogenic qPCR screens 1.) qPCR screening of clonal amplicon libraries generally yields high variation, but considering the bulk population with HDR efficiency of about 1%, there are 1-3 low Ct outlier wells. See below for example data: (See Figure 8). 2.) Once left-shifted Ct outliers are identified, the corresponding wells are expanded in replicate plates following the protocol outlined in Ve. 3.) Once selected wells are expanded and confluent, lyse a portion of the cells and prepare an amplicon library. These are sent to be sequenced via Sanger sequencing. Analyze the intended mutation site in the chromatogram results. Heterozygous mutations will show a double peak at the intended site, while homozygosity will only have the mutant base pair peak. A mixed population of edited and non-edited cells may also appear as a double peak. Additionally, CRISPR-mediated insertions and deletions (indels) will produce additional peaks throughout the region close to the PAM site. Detailed analysis of the chromatogram is necessary to understand the genetic nature of the cell population. See Figure 9.
[0075] Sequence Listing SEQ ID NO:1: cas9_wt [ka] [ka]
[0076] SEQ ID NO:2- cas9_D10A [ka] [ka]
[0077] SEQ ID NO:3- cas9_H840A [ka] [ka]
[0078] SEQ ID NO:4- cas9_D10A_H840A [ka] [ka]
[0079] References: [ka] [ka] [ka] [ka]
[0080] All references cited in this application are hereby incorporated by reference.
[0081] When a range of values is provided, it is understood that each intervening value between the upper and lower limit of that range and any other stated or intervening value in that stated range, to the tenth of the unit of the lower limit, unless the context clearly dictates otherwise, is encompassed within the invention. The upper and lower limits of these smaller ranges may be independently included within the smaller ranges, and are also encompassed within the invention, subject to any specifically excluded boundary in the stated range. Where the stated range includes one or both of its boundaries, ranges excluding either or both of those included boundaries are also encompassed within the invention.
[0082] A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications can be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims. In certain embodiments, for example, the following items are provided: (Item 1) A method for genome editing using a combination of synthetic mRNA and sgRNA encoding the Cas9 enzyme. (Item 2) 2. The method of claim 1, wherein the mRNA and sgRNA encoding Cas9 comprise a 5' diguanosine cap and a poly(A) tail. (Item 3) The method of claim 1, further comprising providing a template that promotes DNA cleavage. (Item 4) 4. The method of claim 3, wherein the template is a double-stranded DNA molecule. (Item 5) 3. The method of claim 2, wherein the template is a single-stranded DNA molecule. (Item 6) 3. The method of claim 2, wherein the template is an RNA molecule. (Item 7) 2. The method of claim 1, wherein Cas9 has a mutation that destroys one of the two endonuclease active sites, SEQ ID NO:2, or SEQ ID NO:3. (Item 8) 2. The method of claim 1, wherein Cas9 has a mutation, SEQ ID NO:4, that destroys both endonuclease active sites. (Item 9) 2. The method of claim 1, wherein Cas9 is fused to another enzyme that can alter epigenetic markers in either DNA or chromatin proteins. (Item 10) 2. The method of claim 1, wherein the Cas9 mRNA comprises modified nucleotides. (Item 11) 2. The method of claim 1, wherein the sgRNA comprises modified nucleotides. (Item 12) 11. The method of claim 9 or 10, wherein the modified nucleotide comprises 5-methyl-cytosine, 2-thio-uracil, or pseudouracil. (Item 13) The method according to item 1, wherein the molar ratio between Cas9 mRNA:sgRNA is between 1:1,000 and 1,000:1. (Item 14) The method of claim 1, wherein multiple sgRNAs targeting different sites are introduced into the same cell in combination with mRNA molecules encoding one or more different Cas9 enzymes derived from different species or with different mutations. (Item 15) The method of claim 2, wherein the repair template is positioned at the DNA cleavage site via fusion to an sgRNA as a single molecule. (Item 16) 3. The method of claim 2, wherein the repair template is positioned at the DNA cleavage site via fusion to an aptamer that binds Cas9. (Item 17) The method according to item 1, wherein the method also includes the step of adding B18R. (Item 18) A Cas9 protein having a mutation that is not naturally occurring and that destroys one of the two Cas9 endonuclease active sites, wherein said mutated Cas9 protein is encoded by the DNA of SEQ ID NO:2. (Item 19) A Cas9 protein having a mutation that is not naturally occurring and that destroys one of the two Cas9 endonuclease active sites, wherein said mutated Cas9 protein is encoded by the DNA of SEQ ID NO:3. (Item 20) 1. A Cas9 protein having a mutation that is not naturally occurring and that destroys both CAS9 endonuclease active sites, wherein said mutated Cas9 protein is a Cas9 protein encoded by SEQ ID NO:4. (Item 21) A naturally occurring mRNA encoding a mutated Cas9 protein having a mutation in its nuclease gene, and at least one mRNA encoding a guide RNA. A CRISPER-Cas system that, upon entering a cell, produces the mutated Cas9 protein and guide RNA, which targets and hybridizes to a target sequence of DNA having a single point mutation, and corrects the mutation in the target sequence upon action of the mutated Cas9 protein and guide RNA. (Item 22) 23. The method of claim 22, wherein the cas9 mRNA comprises one or more modified nucleotides. (Item 23) 23. The method of claim 22, wherein the cas9 mRNA and the guide mRNA are transfected into a cell. (Item 24) 25. The method of claim 24, wherein the transfection is carried out in the presence of B18R. (Item 25) Cas9 variants shown in accordance with SEQ ID NOs: 2-4. (Item 26) 26. An engineered, non-naturally occurring, all-RNA, vector-free, virus-free, CRISPR / Cas system for gene editing comprising the cas 9 variant of item 25. (Item 27) 1. A method for altering expression of at least one gene product, the method comprising introducing a vector-free, virus-free, engineered, non-naturally occurring, all-RNA, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-CRISPR-associated (Cas) (CRISPR-Cas) system into a eukaryotic cell that contains and expresses a DNA molecule having a target sequence and encoding the gene product. (Item 28) 20. The method according to item 19, further comprising a cas 9 variant of SEQ ID NO: 2 to 4. (Item 29) A kit comprising an engineered, programmable, non-naturally occurring, all-RNA CRISPR-Cas system comprising a Cas 9 protein as set forth in SEQ ID NOs: 1-4, and instructions for use.
Claims
[Claim 1] The invention described in the specification.
Citation Information
Patent Citations
Inhibition of innate immune response
US20140227300A1
Optimized crispr-CAS double nickase systems, methods and compositions for sequence manipulation
US20160153006A1
COMPOSITIONS COMPRISING SYNTHETIC POLYNUCLEOTIDES ENCODING CRISPR RELATED PROTEINS AND SYNTHETIC SGRNAs AND METHODS OF USE
US20160367702A1
Crispr / CAS-related methods, compositions and components
WO2016154596A1
Methods for increasing the efficiency of homology directed repair (HDR) in the cellular genome
WO2018119060A1
